Outcome of joint negotiations for Zolgensma
Bluebird to pull gene therapies from EU, UK as it prepares European exit
NICE ME/CFS guideline outlines steps for better diagnosis and management
What is a hazard ratio and why is it important for HTA agencies?
Discover the latest developments in AIFA reform as delays persist with the extension of CTS and CPR ...
French government's ambitious plan to save €1 billion in healthcare expenses by 2024 through new r...
Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.
Remap Consulting have significant experience working with pharmaceutical and biotech companies in helping them navigate global market access.